Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + losartan
- Development stage
- Phase 4
- Lead developer
- Second Affiliated Hospital of Xi'an Jiaotong University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lenvatinib + losartan is a combination therapy being investigated as a postoperative adjuvant treatment for hepatocellular carcinoma (HCC), specifically in patients with positive tumor budding. Lenvatinib is a potent multi-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET, thereby inhibiting tumor angiogenesis and proliferation. Losartan, traditionally an angiotensin II receptor blocker (ARB) used for hypertension, is utilized in this context for its ability to degrade collagen barriers within the peritumoral stroma. This "collagen degradation therapy" is intended to reduce the physical resistance of the tumor microenvironment, facilitating better delivery and penetration of lenvatinib into tumor-bottle lesions. The combination is currently being evaluated in a Phase 4 clinical trial led by the Second Affiliated Hospital of Xi'an Jiaotong University to improve survival outcomes and reduce recurrence rates in high-risk HCC patients.
- Other names
- Lenvatinib and Losartan Adjuvant TherapyLenvatinib + losartan
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)AGTR2 (AT2)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib + losartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + losartan.